Alzheimer's disease (AD) is a hard process for patients, caregivers, and a threat to national health systems. It represents 60-80% of the 46.8 million cases of dementia worldwide. Diagnosed in advanced stages, early detection is essential to prevent severe damage of the brain, and to demonstrate new AD drug's efficacy in clinical trials. ADmit is the first IVD test for the early detection of AD even in the absence of signs of dementia. ADmit is protected by patent. Our main competitive advantage is the early detection of AD before the appearance of cerebral abnormal protein aggregates using a non-invasive technique. The test measures a pool of mitochondrial biomarkers in blood samples using next generation sequencing techniques.